News & Updates

Show Multimedia Only

Liraglutide may prevent peripheral artery disease progression in type 2 diabetes

22 Mar 2024

In the treatment of patients with type 2 diabetes and peripheral artery disease (PAD), a 6-month course of liraglutide results in increased peripheral perfusion, according to the results of an open-label study.

Liraglutide may prevent peripheral artery disease progression in type 2 diabetes

22 Mar 2024

Delgocitinib cream a win for adults with chronic hand eczema

22 Mar 2024 by

Twice-daily application of delgocitinib cream, a topical pan-Janus kinase inhibitor, works for adults with moderate-to-severe chronic hand eczema (CHE) compared with a vehicle cream, according to the pooled analysis of the phase III DELTA-1 and -2 trials presented at AAD 2024.

Delgocitinib cream a win for adults with chronic hand eczema

22 Mar 2024

Low-dose semaglutide spurs MASLD regression in people with HIV

21 Mar 2024 by

Treatment with low-dose semaglutide helps reduce the severity of metabolic dysfunction-associated steatotic liver disease (MASLD) in people with HIV, according to data from the single-arm phase IIb ACTG A5371 trial.

Low-dose semaglutide spurs MASLD regression in people with HIV

21 Mar 2024

Rifaximin eases bloating in patients with functional GI disorder

21 Mar 2024

Treatment with rifaximin appears effective in reducing bloating and distension, as well as the subjective severity of these symptoms, in patients with functional gastrointestinal disorder (FGID), results of a systematic review and meta-analysis have shown.

Rifaximin eases bloating in patients with functional GI disorder

21 Mar 2024

Bulevirtide works well against chronic hepatitis D, HIV/HBV/HDV coinfection

21 Mar 2024 by

Patients with hepatitis delta virus (HDV) show increased virologic and biochemical responses with longer bulevirtide (BLV) treatment for over 96 weeks, with no new safety concerns, as shown in a study presented at CROI 2024.

Bulevirtide works well against chronic hepatitis D, HIV/HBV/HDV coinfection

21 Mar 2024

The Pharmacist Healthcare Leadership Forum 2024 prepares pharmacists for leadership roles

21 Mar 2024

The first-ever Pharmacist Healthcare Leadership Forum, organized by the Hospital and Clinical Pharmacy Chapter of the Malaysian Pharmacists Society and supported by MIMS as the media partner, was a resounding success.

The Pharmacist Healthcare Leadership Forum 2024 prepares pharmacists for leadership roles

21 Mar 2024

Vitamin B6 best bet against antipsychotic-induced akathisia

20 Mar 2024 by

Mirtazapine, biperiden, and vitamin B6 are all beneficial in the treatment of antipsychotic-induced akathisia (AIA), with vitamin B6 having the best efficacy and tolerability profile, according to the results of a meta-analysis.

Vitamin B6 best bet against antipsychotic-induced akathisia

20 Mar 2024

COVID-19 rebound common following treatment with either VV116 or nirmatrelvir-ritonavir

20 Mar 2024

Among patients with mild-to-moderate COVID-19, viral rebound and symptom rebound occur frequently following a standard 5-day course of treatment with either VV116 or nirmatrelvir-ritonavir, as shown in a study from China.

COVID-19 rebound common following treatment with either VV116 or nirmatrelvir-ritonavir

20 Mar 2024

Original New Drug Application Approvals by US FDA (1-15 March 2024)

20 Mar 2024

New drug applications approved by US FDA as of 1-15 March 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (1-15 March 2024)

20 Mar 2024

Low-dose continuous kidney replacement therapy ups mortality in critically ill patients

19 Mar 2024

A lower delivered continuous kidney replacement therapy (CKRT) dose appears to be detrimental to critically ill patients with acute kidney injury (AKI), with a study showing that such an approach is associated with a higher 90-day mortality rate.

Low-dose continuous kidney replacement therapy ups mortality in critically ill patients

19 Mar 2024

News & Updates

Filter by Specialty:

Specialty:

Liraglutide may prevent peripheral artery disease progression in type 2 diabetes

Liraglutide may prevent peripheral artery disease progression in type 2 diabetes

Delgocitinib cream a win for adults with chronic hand eczema

Delgocitinib cream a win for adults with chronic hand eczema

Low-dose semaglutide spurs MASLD regression in people with HIV

Low-dose semaglutide spurs MASLD regression in people with HIV

Rifaximin eases bloating in patients with functional GI disorder

Rifaximin eases bloating in patients with functional GI disorder

Bulevirtide works well against chronic hepatitis D, HIV/HBV/HDV coinfection

Bulevirtide works well against chronic hepatitis D, HIV/HBV/HDV coinfection

The Pharmacist Healthcare Leadership Forum 2024 prepares pharmacists for leadership roles

The Pharmacist Healthcare Leadership Forum 2024 prepares pharmacists for leadership roles

Vitamin B6 best bet against antipsychotic-induced akathisia

Vitamin B6 best bet against antipsychotic-induced akathisia

COVID-19 rebound common following treatment with either VV116 or nirmatrelvir-ritonavir

COVID-19 rebound common following treatment with either VV116 or nirmatrelvir-ritonavir

Original New Drug Application Approvals by US FDA (1-15 March 2024)

Original New Drug Application Approvals by US FDA (1-15 March 2024)

Low-dose continuous kidney replacement therapy ups mortality in critically ill patients

Low-dose continuous kidney replacement therapy ups mortality in critically ill patients